BioSyent Inc. (BIOYF)
BIOYF Stock Price Chart
Explore BioSyent Inc. interactive price chart. Choose custom timeframes to analyze BIOYF price movements and trends.
BIOYF Company Profile
Discover essential business fundamentals and corporate details for BioSyent Inc. (BIOYF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
22 Feb 2012
Employees
60.00
Website
https://www.biosyent.comCEO
René C. Goehrum
Description
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.
BIOYF Financial Timeline
Browse a chronological timeline of BioSyent Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Mar 2026
Upcoming earnings on 11 Mar 2026
Upcoming earnings on 19 Nov 2025
Revenue estimate is $10.10M.
Earnings released on 21 Aug 2025
EPS came in at $0.13 , while revenue for the quarter reached $7.47M , missing expectations by -23.76%.
Dividend declared on 21 Aug 2025
A dividend of $0.04 per share was announced, adjusted to $0.04. The dividend will be paid on 15 Sept 2025.
Earnings released on 15 May 2025
EPS came in at $0.14 , while revenue for the quarter reached $7.71M , missing expectations by -25.87%.
Dividend declared on 15 May 2025
A dividend of $0.04 per share was announced, adjusted to $0.04. The dividend was paid on 13 Jun 2025.
Earnings released on 11 Mar 2025
EPS came in at $0.10 falling short of the estimated $0.10 by -8.79%, while revenue for the quarter reached $6.11M , missing expectations by -32.83%.
Dividend declared on 28 Feb 2025
A dividend of $0.03 per share was announced, adjusted to $0.03. The dividend was paid on 14 Mar 2025.
Dividend declared on 29 Nov 2024
A dividend of $0.03 per share was announced, adjusted to $0.03. The dividend was paid on 16 Dec 2024.
Earnings released on 20 Nov 2024
EPS came in at $0.15 surpassing the estimated $0.10 by +42.80%, while revenue for the quarter reached $24.34M , beating expectations by +167.51%.
Dividend declared on 4 Sept 2024
A dividend of $0.03 per share was announced, adjusted to $0.03. The dividend was paid on 15 Sept 2024.
Earnings released on 26 Aug 2024
EPS came in at $0.10 surpassing the estimated $0.09 by +3.16%, while revenue for the quarter reached $6.54M , beating expectations by +1.74%.
Dividend declared on 31 May 2024
A dividend of $0.03 per share was announced, adjusted to $0.03. The dividend was paid on 15 Jun 2024.
Earnings released on 16 May 2024
EPS came in at $0.11 surpassing the estimated $0.06 by +85.74%, while revenue for the quarter reached $5.70M , missing expectations by -2.34%.
Earnings released on 13 Mar 2024
EPS came in at $0.09 falling short of the estimated $0.13 by -27.48%, while revenue for the quarter reached $6.23M , missing expectations by -6.18%.
Dividend declared on 22 Feb 2024
A dividend of $0.03 per share was announced, adjusted to $0.03. The dividend was paid on 15 Mar 2024.
Dividend declared on 22 Nov 2023
A dividend of $0.03 per share was announced, adjusted to $0.03. The dividend was paid on 15 Dec 2023.
Earnings released on 16 Nov 2023
EPS came in at $0.14 surpassing the estimated $0.07 by +95.63%, while revenue for the quarter reached $6.55M , beating expectations by +8.50%.
Dividend declared on 24 Aug 2023
A dividend of $0.03 per share was announced, adjusted to $0.03. The dividend was paid on 15 Sept 2023.
Earnings released on 22 Aug 2023
EPS came in at $0.09 surpassing the estimated $0.09 by +0.72%, while revenue for the quarter reached $6.01M , beating expectations by +3.48%.
Dividend declared on 27 May 2023
A dividend of $0.03 per share was announced, adjusted to $0.03. The dividend was paid on 15 Jun 2023.
Earnings released on 26 May 2023
EPS came in at $0.07 falling short of the estimated $0.10 by -26.79%, while revenue for the quarter reached $4.79M , missing expectations by -14.75%.
Earnings released on 21 Mar 2023
EPS came in at $0.09 falling short of the estimated $0.10 by -10.00%, while revenue for the quarter reached $5.56M , beating expectations by +9.25%.
Dividend declared on 18 Feb 2023
A dividend of $0.03 per share was announced, adjusted to $0.03. The dividend was paid on 15 Mar 2023.
Dividend declared on 22 Nov 2022
A dividend of $0.03 per share was announced, adjusted to $0.03. The dividend was paid on 15 Dec 2022.
Earnings released on 15 Nov 2022
EPS came in at $0.12 falling short of the estimated $0.13 by -7.69%, while revenue for the quarter reached $4.96M , missing expectations by -1.96%.
Earnings released on 23 Aug 2022
EPS came in at $0.10 falling short of the estimated $0.14 by -28.57%, while revenue for the quarter reached $5.15M , missing expectations by -11.55%.
Earnings released on 18 May 2022
EPS came in at $0.13 surpassing the estimated $0.11 by +18.18%, while revenue for the quarter reached $5.63M , beating expectations by +0.62%.
Earnings released on 8 Mar 2022
EPS came in at $0.15 surpassing the estimated $0.11 by +36.36%, while revenue for the quarter reached $5.66M , beating expectations by +3.77%.
Earnings released on 18 Nov 2021
EPS came in at $0.13 surpassing the estimated $0.10 by +30.00%, while revenue for the quarter reached $5.28M .
Earnings released on 25 Aug 2021
EPS came in at $0.08 falling short of the estimated $0.10 by -20.00%, while revenue for the quarter reached $5.88M .
Earnings released on 27 May 2021
EPS came in at $0.13 surpassing the estimated $0.09 by +44.44%, while revenue for the quarter reached $5.90M .
Earnings released on 17 Mar 2021
EPS came in at $0.05 falling short of the estimated $0.08 by -37.50%, while revenue for the quarter reached $4.49M .
Earnings released on 26 Nov 2020
EPS came in at $0.07 falling short of the estimated $0.09 by -22.22%, while revenue for the quarter reached $4.34M .
BIOYF Stock Performance
Access detailed BIOYF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.